Rudas S, Schmitz M, Pichler P, Baumgartner A
Community Mental Health Service of Vienna, Austria.
Biol Psychiatry. 1999 Jan 15;45(2):229-33. doi: 10.1016/s0006-3223(98)00033-x.
An 8-week open trial was conducted to investigate whether patients with treatment-resistant, chronic depression and/or dysthymia could profit from high-dose thyroxine (T4) augmentation.
Nine patients whose current depressive episode had lasted for a mean of 15.5 +/- 8.6 months (range: 2-30 months) received T4 in addition to their current medication.
Two patients dropped out of the study owing to side effects. The remaining 7 patients received a final mean dose of T4 of 235 +/- 58 micrograms/day (range: 150-300 micrograms/day). Their scores on the Hamilton Depression Rating Scale had fallen from a mean of 21.1 +/- 4.1 before inclusion in the study to a mean of 8.0 +/- 2.8 at the end of the 8th week. Five patients were full responders, 1 a partial responder, and 1 a nonresponder.
Augmentation with high-dose T4 proved to have an antidepressant effect in more than 50% of the previously treatment-resistant patients with chronic depression and/or dysthymia.
进行了一项为期8周的开放性试验，以调查对治疗有抵抗性的慢性抑郁症和/或心境恶劣障碍患者是否能从高剂量甲状腺素（T4）增效治疗中获益。
9例当前抑郁发作平均持续15.5±8.6个月（范围：2 - 30个月）的患者，在当前用药基础上加用T4。
2例患者因副作用退出研究。其余7例患者最终T4平均剂量为235±58微克/天（范围：150 - 300微克/天）。他们的汉密尔顿抑郁量表评分从纳入研究前的平均21.1±4.1降至第8周结束时的平均8.0±2.8。5例患者为完全缓解者，1例为部分缓解者，1例为无反应者。
高剂量T4增效治疗对超过50%先前对治疗有抵抗性的慢性抑郁症和/或心境恶劣障碍患者有抗抑郁作用。
